We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
News

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
News

Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar Biotechnologies, Inc. has announced the issuance of two additional patents, in the United States and in China, covering the Company’s active immunotherapy technology for the treatment of Clostridium difficile infection (“C. diff”).

Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The two patents, U.S. patent No. 8,597,663 and China patent No. 200880115518.2, describe certain novel cell surface polysaccharides and their chemical structures with broad claims covering antigen and vaccine compositions for the treatment, prevention and diagnosis of C. diff infection.

Stellar holds the exclusive, worldwide rights to develop, manufacture and sell human vaccines and other products derived from these patents, licensed from the University of Guelph. The license covers intellectual property related to the cell-wall polysaccharide of C. diff named PSII.

Stellar’s technology combines PSII with Stellar KLH™ into an active immunotherapy approach with potential advantages over other technologies.

“Our PSII-KLH technology is dramatically different from other approaches,” said Herbert Chow, Ph.D., Stellar’s Chief Technology Officer. “We are harnessing the body’s own immune system to disrupt the fundamental pathways of C. diff pathogenesis and transmission, unlike many methods which can only impact disease symptoms. These patents strengthen Stellar’s intellectual property and further raise the barriers around our C. diff platform.”

The novel combination of PSII-KLH is designed to activate innate and adaptive immune systems in the intestines that directly inhibit spore germination and reduce bacterial burden.

In this way, Stellar’s PSII-KLH vaccine is cell-directed to limit the extent and spread of disease transmission. Preliminary preclinical studies from Stellar’s PSII-KLH active immunotherapy program demonstrated protection against C. diff in mice.

Advertisement